Screener / SEC EDGAR /CIK 0001821825 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Organon & Co. OGN

Compare with peers Embed
The 10-K against last year's

239 changes: 80 added, 43 removed, 112 reworded, 4 quiet changes

10-K Feb 24, 2026 vs Feb 28, 2025

10-K 0001628280-26-011125 (Feb 24, 2026) vs 10-K 0001821825-25-000006 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

247 paragraphs · 55 new · 96 reworded · 18 gone · 10-K Feb 24, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 158 · 49% changed Every version of it
Even after a pharmaceutical product or medical device reaches the market, we continue to be subject to significant post-marketing regulatory requirements and oversight. The regulatory approvals or marketing authorizations that we may receive for our pharmaceutical products and medical devices will require the submission of reports to regulatory authorities and on-going surveillance to monitor the safety and efficacy of our products, may contain significant limitations related to use restrictions for specified groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. In addition, even after a pharmaceutical product or device has obtained marketing authorization or clearance, the manufacturing processes, labeling, packaging, distribution, adverse event and device malfunction reporting, storage, advertising, promotion, import, export, recalls and recordkeeping for our products will be subject to ongoing regulatory requirements, and we will be subject to periodic inspections. Failure to comply with any of these requirements could subject us to a variety of formal or informal enforcement actions by the FDA or other regulators, result in a recall or market withdrawal of our products, require us to cease manufacturing and distribution of the products, trigger product liability or other litigation, or otherwise impact our ability to realize revenues for our products. For example, in January 2023, we voluntarily initiated market actions, including recalls, in certain markets with respect to our suspension injections Diprospan, Celestone ChronodoseTM 1 (betamethasone) and Celestone Soluspan® (betamethasone) related to a non-conforming component of a manufacturing line at our Heist, Belgium plant. It is possible that future recalls or similar developments could materially and adversely impact our business, result of operations, and or financial condition. Although to date, any market actions to which we have been subject have not had a material impact on our business, such actions could in the future have a materially adverse impact on our business, results of operations, and or financial condition.
Paragraph 118 · 48% changed Every version of it
We believe that the health care industry will continue to be Our sales of Nexplanon have already been impacted by judicial decisions, increasing regulation, political unfavorable U.S. policies, budget constraints, and legal action at both funding for Planned Parenthood and federally qualified health centers, where Nexplanon has a leading market share among long-acting reversible contraceptives. Going forward, we expect to see continued focus by the federal U.S. government and state/local levels in the United States states, as well as non-U.S. governments and internationally, regulatory authorities, on regulating drug pricing and US executive orders. access to medicines and other healthcare products. While it is uncertain how such developments will affect our business, they could, at a minimum, introduce additional uncertainty into the regulatory process, result in legal challenges to actions taken by regulatory agencies, bodies, and subject us to additional pricing pressures.
Paragraph 111 · 46% changed Every version of it
We face continued pricing pressure in the United States and globally and, particularly (particularly in the EU, the United Kingdom, UK, China and Japan, Japan) from managed care organizations, government agencies and programs that programs, as these governments and third-party payors are becoming increasingly aggressive in attempting to contain healthcare costs by strictly controlling, directly or indirectly, pricing and reimbursement and, in some cases, limiting or denying coverage altogether on the basis of a variety of justifications. We expect pressures on pricing and reimbursement from both governments and private payors inside and outside the United States to continue, which could adversely affect our sales and profit margins. We expect pricing pressure to continue in the future.
Paragraph 116 · 46% changed Every version of it
For instance, changes to the health care system enacted as part of health care reform in the United States and The increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid Medicaid, private insurance programs and private sector beneficiaries pharmacy benefit managers could result in further pricing pressures. Health We must also compete to be placed on formularies of managed care organizations and other payors. Exclusion of a product from a formulary can lead to reduced usage in the population covered by the managed care organization or other payor. U.S. healthcare reform has already contributed to an increase in the number of patients in the Medicaid program under which sales of pharmaceutical products are subject to substantial rebates. There are pending also ongoing legal and legislative policy developments relating to the 340B Drug Pricing Program, including ongoing litigation challenging state 340B laws that seek to limit manufacturer contract pharmacy policies. Additionally, the Health Resources and Services Administration’s new 340B Rebate Model Pilot Program could introduce a shift in how discounts are provided to 340B covered entities. While the implementation of this program was enjoined by a federal enforcement actions against manufacturers court prior to its effectiveness, such a rebate model could allow for greater transparency and recently introduced and enacted state legislation. improved program compliance. Any changes to the 340B Program could have a significant impact on our revenue from affected products.
Paragraph 186 · 45% changed Every version of it
We have adopted a comprehensive global privacy program to help manage these evolving risks, adjust to Any of the changing regulatory landscape and facilitate CBDTs. Any failure by us, or our third-party vendors, to comply with applicable data privacy and security laws may lead to government enforcement actions and private litigation, which foregoing could result in financial, legal, business, product shortages, lost sales, government agency actions, and reputational harm to us and us, which could have a material adverse effect on our business, results of operations, and or financial condition.
Paragraph 42 · 45% changed Every version of it
•Our global business could be negatively impacted by corporate citizenship and sustainability matters. matters, which are viewed differently by the U.S. presidential administration and certain U.S. states than under various EU frameworks.
Paragraph 215 · 45% changed Every version of it
Our global business could be negatively impacted by corporate citizenship and sustainability matters. matters, which are viewed differently by the U.S. presidential administration and certain U.S. states than under various EU frameworks.
Paragraph 19 · 45% changed Every version of it
•We have incurred substantial indebtedness, which •An impairment of our Goodwill could adversely affect materially impact our financial condition and results of operations.

MD&A

137 paragraphs · 25 new · 74 reworded · 25 gone · 10-K Feb 24, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 49 · 49% changed
Sales •Vtama, as a result of Vtama a cream for the topical treatment of mild, moderate, and severe plaque psoriasis in adults were $12 million for the year ended December 31, 2024, reflecting the our acquisition of Dermavant in the fourth quarter of 2024. 2024, launch of the atopic dermatitis indication for adults and children two years of age and older in the United States and launch of the topical treatment of plaque psoriasis in adults in Canada in the third quarter of 2025;
Paragraph 128 · 43% changed
To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs. Businesses acquired are consolidated upon obtaining control. The fair value of assets acquired and liabilities assumed are recognized at the date of acquisition. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. Business acquisition costs are expensed when incurred.
Paragraph 83 · 41% changed
Exchange losses decreased 38% 46% for the year ended December 31, 2024, 2025, compared to 2023, driven by less volatility 2024, primarily due to favorable movements in certain foreign exchange compared currencies relative to the prior year and the favorable changes in spot rates of our forward contracts. U.S. dollar.
Paragraph 92 · 40% changed
Net cash used in financing activities was $368 $561 million for the year ended December 31, 2024, 2025, compared to $569 with $368 million for the same period in the prior year. The decrease in cash used in financing activities was year, primarily driven by the $250 repurchase and cancellation of $419 million voluntary prepayment of the 2031 Notes and the payment and termination of the NovaQuest Funding Agreement, partially offset by borrowings on the U.S. dollar-denominated term loan our Revolving Credit Facility, decreased dividend payments in the current year ended December 31, 2023, compared to a $7.5 million discretionary prepayment on the U.S. dollar-denominated term loan and $38 million of no debt issuance costs related compared to the long-term debt refinancing in the year ended December 31, 2024. prior period.
Paragraph 124 · 40% changed
Goodwill represents Indefinite-lived intangibles acquired in conjunction with the excess acquisition of a business are initially recorded at fair value. We evaluate the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is evaluated indefinite-lived intangibles for impairment as of October 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying value. amount. Some of the factors and indicators considered in the assessment include general macroeconomic conditions, conditions specific to regulatory and status of clinical testing, commercial and competitive landscape, legal and financial considerations for the industry and market, cost factors which could have a significant effect on earnings or cash flows, and overall financial performance. indefinite-lived intangibles. If we conclude it is more likely than not that the fair value is less than its carrying value, amount, a quantitative fair value impairment test is performed. If carrying value is greater than fair value, a goodwill an impairment charge will be recorded for the difference (up to the carrying value of goodwill). difference. We completed the annual qualitative goodwill impairment test as in the fourth quarter of October 1, 2024 2025 and concluded that there was no impairment to goodwill as the fair value of the reporting unit was significantly in excess of the carrying value. indefinite-lived intangibles.
Paragraph 52 · 39% changed
Worldwide sales of Follistim AQ, a fertility treatment, declined 10% for the year ended December 31, 2024, compared to 2023, •Follistim, due to a one-time buy-in as a result of our exit from our interim operating model agreement in the United States with Merck, during the fourth quarter of 2023, and unfavorable discount rates increased demand in the United States, partially offset by increased a decrease in demand in China. Comparability of sales for the United States and launches year ended December 31, 2025, is impacted by a one-time buy-in that occurred in various international markets. the fourth quarter of 2023. This buy-in, a consequence of exiting our interim operating model agreement with Merck, resulted in a reduction of sales in the first half of 2024.
Paragraph 72 · 35% changed
Sales of Vtama Vtama, a cream for the topical treatment of mild, moderate, and severe plaque psoriasis in adults and atopic dermatitis, also known as eczema, in adults and children two years of age and older, were $12 $128 million for the year ended December 31, 2024, reflecting the 2025, as a result of our acquisition of Dermavant in the fourth quarter of 2024. 2024, launch of the atopic dermatitis indication for adults and children two years of age and older in the United States and launch of the topical treatment of plaque psoriasis in adults in Canada in the third quarter of 2025. We anticipate launching Vtama in certain international markets in 2026 and beyond.
Paragraph 82 · 34% changed
Interest expense decreased 1% 3% for the year ended December 31, 2024, 2025, compared to 2023, reflecting 2024, and reflects lower interest rates as a result of refinancing a portion of our long-term debt in the prior year and the impact repurchase and cancellation of approximately $419 million of the 2031 Notes during the second and fourth quarters of 2025 combined with lower reference rates on our cross-currency swaps, partially variable rate debt, offset by interest related to the debt acquired as part of the Dermavant acquisition and approximately $6 million in previously unamortized debt issuance costs related to fees of approximately $3 million associated with the refinancing repurchase and cancellation of our long-term debt. Beginning in May 2024, approximately $419 million of the difference between the interest rate received of 7.3125% and paid of 5.8330% under the cross-currency swap agreements is recorded in Interest expense. 2031 Notes.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors252 words changed in this paragraph; it is 54% similar to last year's version.
Our ability to generate profits and operating cash flow depends largely upon the continued profitability of our key products, such as Nexplanon, Arcoxia, Singulair and Vtama, Emgality, the ezetimibe family of products. products and our portfolio of biosimilars. As a result of our dependence on key products, any event that adversely affects any of these products or the markets for any of these products could adversely affect our sales, results of operations or cash flows. These adverse events could include increased costs associated with manufacturing, product shortages, increased generic or over-the-counter availability of our products or competitive products, the discovery of previously unknown side effects, effects or the implementation of enhanced safety measures and/or warnings, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of these products for any reason. In addition, recent adverse market and political events could negatively impact our key products and/or our business, results of operations and financial condition as a whole. Such adverse events may include, among other things, U.S. and international tariffs or other protectionist trade measures, the recent changes to U.S. tax laws, healthcare and regulatory reforms, including those relating to insurance coverage, and other U.S. and international regulatory changes, including changes in the regulatory enforcement landscape. Our future sales of Nexplanon could be affected by a REMS, which FDA has required for the product in connection with the new five-year duration of use. The REMS seeks to reduce risks of improper insertion and removal of the product and requires, among other things, that healthcare providers enroll in the REMS program following specific training in order to maintain access to the product. We are seeking an additional period of exclusivity for Nexplanon, specifically the potential additional three years of New Clinical Investigation exclusivity for Nexplanon in the United States for the five-year duration of use indication, which is currently under FDA review. Sales may also be adversely affected if this exclusivity was not to be granted. We also expect that competition will continue to adversely affect the sales of these products (including our key products, this includes generic competition as a result of LOE in 2024 2026 for Atozet and, if Nexplanon in markets outside the US, although we are unable have yet to obtain an additional period see the commercial launches of market exclusivity for Nexplanon). generic Nexplanon.

Source: Item 1A, 10-K 0001628280-26-011125 vs Item 1A, 10-K 0001821825-25-000006

MD&A168 words changed in this paragraph; it is 35% similar to last year's version.
In December 2023, March 2025, we announced an agreement with Lilly acquired from Biogen the regulatory and commercial rights in the United States for Tofidence, a biosimilar to become Actemra2 (tocilizumab), for intravenous infusion. Tofidence, launched in the sole distributor U.S. market in May 2024, is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and promoter of the migraine medicines Emgality and Rayvow in Europe. Lilly will remain the marketing authorization holder and will manufacture the products for sale. COVID-19. Under the terms of the agreement, agreement with Biogen, we paid an upfront payment of $50 $51 million upon closing in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the transaction in January 2024, and will recognize sales-based milestones when the achievement is deemed probable. product developer for Tofidence. In the first quarter of 2024, 2025, we recognized an intangible asset of $220 $51 million, comprised of related to the $50 million upfront payment and $170 million of sales-based milestones that were deemed probable. The intangible asset to Biogen, which will be amortized over 10 years.

Source: Item 7, 10-K 0001628280-26-011125 vs Item 7, 10-K 0001821825-25-000006

Accounting Policies150 words changed in this paragraph; it is 63% similar to last year's version.
Contingent Consideration — For transactions accounted for as a business combination, acquisition, contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in Other expense, net in the Consolidated Statements of Income. Contingent consideration liabilities that are payable prior to regulatory approval are recognized in Research and development in the Consolidated Statements of Income when achievement of the milestone is deemed probable. Contingent consideration liabilities that are payable on or after regulatory approval are capitalized as intangible assets when the payments have become probable and amortized to Cost of sales over the remaining useful life of the related intangible assets. Contingent consideration payments made or received soon after the acquisition date are classified as Investing activities in the Consolidated Statements of Cash Flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as Financing activities in the Consolidated Statements of Cash Flows, and amounts paid or received in excess of the original acquisition date fair value are reported as Operating activities in the Consolidated Statements of Cash Flows. For transactions accounted for as an asset acquisition, contingent consideration liabilities that are payable prior to regulatory approval are recognized in Acquired in-process research and development and milestones in the Consolidated Statements of Income when achievement of the milestone is deemed probable. Contingent consideration liabilities that are payable on or after regulatory approval are capitalized as intangible assets when the payments have become probable and amortized to Cost of sales over the remaining useful life of the related intangible assets.

Source: Item 8, Note 2 – Summary of Accounting Policies, 10-K 0001628280-26-011125 vs Item 8, Note 2 – Summary of Accounting Policies, 10-K 0001821825-25-000006

Legal Proceedings116 words changed in this paragraph; it is 38% similar to last year's version.
All federal cases involving allegations of femur fractures have been transferred to a multidistrict litigation in the U.S. District Court for the District of New Jersey (“Femur Fracture MDL”). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law. The Femur Facture MDL court then dismissed with prejudice approximately 650 cases on these same preemption grounds. Following a series of appeals, including a U.S. Supreme Court decision in 2019, the Third Circuit ruled in September 2024 that plaintiffs’ failure-to-warn claims are not preempted by federal law. Consequently, 975 cases are now before the Femur Fracture MDL court for further litigation.

Source: Item 3, via Note 18 – Contingencies, 10-K 0001628280-26-011125 vs Item 3, via Note 18 – Contingencies, 10-K 0001821825-25-000006

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of OGN's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as any retaliatory actions with respect to such actions, could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, or stock price.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•The completion of the self-initiated Audit Committee (as defined below) internal investigation and the subsequent implementation of our remediation plan has been time-consuming and expensive and may result in significant additional expense and/or litigation.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•We identified material weaknesses in our internal control over financial reporting, which could impact our ability to report our results of operations and financial condition accurately and in a timely manner.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•The use of artificial intelligence (“AI”) and its legislative and regulatory landscape continues to evolve and makes it difficult to fully understand and assess related risks.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•We may not be able to successfully execute our plan to deleverage our business or otherwise reduce our debt level, which could adversely affect our operating flexibility, business, financial condition, results of operations, or cash flows.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•Recent global healthcare reform initiatives and U.S., judicial decisions, laws, regulations, executive orders and political actions could adversely affect our future revenues and profitability.
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 68
AddedRisk Factors
•The FDA’s shift toward “radical transparency,” including plans to release future complete response letters promptly after they are issued to sponsors and increase enforcement in advertising and promotion, could have an adverse impact on our business and adversely affect our commercial prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as any retaliatory actions with respect to such actions, could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, or stock price.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The U.S. presidential administration has reached several bilateral trade agreements that seek to cap tariffs on imports into the U.S., including an agreement with the EU that would limit U.S. tariffs to 15% on certain brand pharmaceutical and to keep tariffs on generic medicines at 0%. The United States may reach additional trade agreements with other trading partners seeking to mitigate the impact of tariffs. In addition, the U.S. Department of Commerce has initiated an investigation under Section 232 of the Trade Expansion Act of 1962, as amended, to determine dependence on imported pharmaceuticals and pharmaceutical ingredients and the impact on national security. This investigation may lead to the imposition of additional tariffs on pharmaceutical imports in 2026.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The imposition of new, announced or proposed tariffs, trade restrictions or domestic sourcing requirements on pharmaceutical imports, including but not limited to products, ingredients, and other materials necessary for our business, could result in increased costs of goods and prices, disruptions to our supply chain, manufacturing delays, supply shortages, and adverse impacts to clinical trials. These measures could also result in decreased profit margins on certain of our products. In particular, any future tariffs on generic drugs, ingredients, or inputs, could significantly decrease profit margins on such products.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
•The health care industry in the United States has been, and will continue to be, subject to judicial decisions and increasing laws, regulation, executive orders and political action.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
•We or our third-party suppliers, logistics, and manufacturers may not comply with ethical business practices or with related laws and regulations, including relating to AI use.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
•Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Changes to the health care system due to health care reform in the United States, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
As of December 31, 2024, we had outstanding indebtedness of approximately $8.9 billion, as described more fully in the Notes to our financial statements. In addition, we may incur additional debt from time to time to finance acquisitions or for other purposes, subject to the restrictions contained in the documents that govern our indebtedness. Current or future levels of indebtedness may increase the possibility that we will be unable to generate cash sufficient to pay amounts due in respect of such indebtedness.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Our ability to issue additional debt or enter into other financing arrangements on acceptable terms could be adversely affected if our operating results or financial condition decline (which could occur if, among other things, there is a material decline in the demand for our products, if our customers or suppliers are unable to pay amounts due to us or there are other significantly unfavorable changes in economic conditions.) Volatility in the world financial markets could increase borrowing costs or affect our ability to access the capital markets. These conditions may adversely affect our ability to obtain and maintain our credit ratings.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
The health care industry in the United States has been, and will continue to be, subject to judicial decisions and increasing laws, regulation, executive orders and political action.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
We cannot predict the likelihood of additional future changes in the health care industry in general, the pharmaceutical industry in particular, or what impact they may have on our business, cash flow, results of operations, financial condition or prospects.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
In February 2022, in response to the armed conflict between Ukraine and Russia, trade sanctions, travel bans and asset/financial freezes were announced by the United States, the EU and other countries against Russian entities and designated individuals. Such restrictions have impacted, and may continue to impact, many global businesses in direct and indirect ways (including, but not limited to, product shipping delays, supply shortages, delays in regulatory approvals and audits and currency exchange rates). Such actions may negatively impact the financial institutions, vendors, manufacturers, suppliers, partners and other third parties with whom we conduct business and therefore may negatively impact us. In addition, although we do not expect the recent Israel-Hamas war and ongoing conflicts in the Middle East region to have a direct material impact on our business, the war and escalating tensions in the region may impact global markets or affect our supply chain.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Counterfeit pharmaceutical products pose a significant risk to patient health and safety because of the conditions under which they are manufactured—often in unregulated, unlicensed, uninspected and unsanitary sites—as well as the lack of regulation of their contents. Failure to mitigate this threat could adversely impact our customers, potentially causing them harm. This, in turn, may result in the loss of confidence in our products’ reputation and integrity, and potentially impact our business through lost sales, product recalls, and possible litigation.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Our operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors that impact our cost structure and revenue results. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflicts in Ukraine and the Middle East, steps taken by governments and central banks, as well as other stimulus and spending programs, have led to higher inflation, which is likely to lead to an increase in costs and may cause changes in fiscal and monetary policy, including increased interest rates. In a higher inflationary environment, we may be unable to raise the prices of our products sufficiently to keep up with the rate of inflation.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
We face continued pricing pressure in the United States and globally and, particularly (particularly in the EU, the United Kingdom, UK, China and Japan, Japan) from managed care organizations, government agencies and programs that could adversely affect our sales programs, as these governments and profit margins. third-party payors are becoming increasingly aggressive in attempting to contain healthcare costs by strictly controlling, directly or indirectly, pricing and reimbursement and, in some cases, limiting or denying coverage altogether on the basis of a variety of justifications.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Any failure by us, or our third-party vendors, to comply with applicable data privacy and security laws may lead to government enforcement actions and private litigation, which of the foregoing could result in financial, legal, business, product shortages, lost sales, government agency actions, and reputational harm to us and us, which could have a material adverse effect on our business, results of operations, and or financial condition.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We have limited in-house discovery and limited cash to pursue early research capabilities and will continue to rely on future acquisitions, partnerships and collaborations to expand any expansion of our innovative pipeline and early discovery and research capabilities, capabilities through future external acquisitions, partnerships and collaborations, which may limit our ability to discover or develop new products or expand our existing products into new markets to replace the sales of products that lose patent protection, and therefore we may not be able to maintain our current levels of profitability. protection.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We also expect that competition will continue to adversely affect the sales of these products (including our key products, this includes generic competition as a result of LOE in 2024 2026 for Atozet and, if Nexplanon in markets outside the US, although we are unable have yet to obtain an additional period see the commercial launches of market exclusivity for Nexplanon). generic Nexplanon.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If our customers' financial conditions are adversely affected, those customers may reduce their purchases of our products or we may not be able to collect accounts receivable, each of which could have a material adverse impact on our business operations or financial results, and we may not be able to fully absorb any such additional costs or revenue declines in the prices for our products and services.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, over in the last few years, fall of 2025, the U.S. government has faced threats of experienced a prolonged shut down several times and certain regulatory agencies, such as including the FDA and the SEC, faced the possibility of furloughing critical FDA, SEC experienced staff reductions and other government employees and stop critical activities. furloughs.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
As the U.S. and foreign federal or local governments shift their pharmaceutical approval and regulatory priorities, including funding allocations, we may encounter challenges receiving key regulatory approvals or maintaining business relationships with third parties that depend on government funding, which could materially adversely affect our business, financial condition, results of operations, and reputation.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We Our research and development of new pharmaceutical product candidates or medical devices going forward will be limited, and for those development projects we elect to pursue we and/or our partners may fail to adequately demonstrate the safety and efficacy of any of our pharmaceutical product candidates or medical devices in pre-clinical studies and clinical trials, which would prevent or delay development, regulatory approval or marketing authorization and commercialization of our product candidates.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For instance, changes to the health care system enacted as part of health care reform in the United States and The increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid Medicaid, private insurance programs and private sector beneficiaries pharmacy benefit managers could result in further pricing pressures.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We expect recent that the OBBBA and additional changes in tax laws around the world, including as led by the Organization for Economic Cooperation and Development, such as the adoption by the EU and the enactment by additional countries of a global minimum tax, to will negatively impact our effective tax rate and results of operations.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
There are pending also ongoing legal and legislative policy developments relating to the 340B Drug Pricing Program, including ongoing litigation challenging federal enforcement actions against manufacturers and recently introduced and enacted state legislation. 340B laws that seek to limit manufacturer contract pharmacy policies.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
However, we We may experience difficulties identifying future acquisition or disposition opportunities or completing such transactions. transactions, including in light of our current capital allocation priority of deploying excess cash to reduce our net leverage ratio.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
If our suppliers, packagers, shippers, manufacturers, or formulators fail to comply with applicable laws, regulations, safety codes, employment practices, human rights standards, quality standards, environmental standards, production practices, or other obligations, norms, or ethical standards, our reputation and brand image could be harmed, and we could be exposed to litigation, investigations, enforcement actions, monetary liability, and additional costs that would could harm our reputation, business, financial condition, results of operations and or prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
The timing, declaration, amount and payment of any future dividends to stockholders will fall falls within the discretion of our Board of Directors, subject to Delaware law.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
•the success of our efforts to adopt our business and sales strategies to address the changing market and regulatory landscape in order to achieve our business objectives and remain competitive;
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
•reduced research and development investment and increased reliance on fewer research and development programs for new products to generate future revenue and replace existing products that come to the end of their market life cycle;
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
•uncertainties surrounding matters relating to the Audit Committee investigation and any related investigations, inquiries, claims, proceedings or actions, as described elsewhere in this 2025 Form 10-K; and
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
•Other Macroeconomic Considerations: Geopolitical developments including changes to the political orientation of the governments in key countries, global trade issues such as tariffs imposed by or on the United States, shifting U.S. federal and state government policies, policies hindering market access, and worsening macroeconomic conditions could impact our business and results of operations and may stress our working capital resources. While tariffs have not, to date, had a material impact on our business, future tariff actions could potentially have a significant effect on our supply chain and operating costs. Regulatory agency developments, including disruptions at the FDA and other agencies, could increase the time needed for review and approval of new drugs and medical devices, potentially impacting our ability to develop new drugs, delaying our product launches and impacting our business operations. Additionally, proposed cuts to Medicaid and changes in federal funding policies could reduce access to healthcare services for low-income individuals. International reference pricing frameworks, including MFN mandates, may further constrain our pricing flexibility and commercial strategy. Voluntary price concessions in certain European markets and increased rebate negotiations across the EU have introduced additional pressure on net pricing and margins. These developments may influence our commercial strategy, constrain pricing flexibility and delay product launches. For additional information, please refer to Item 1A — Risk Factors.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In January 2026, we divested the Jada System to Laborie for an aggregate payment of up to $465 million, comprised of consideration of $440 million, subject to certain closing adjustments, plus potential earnout payments of up to $25 million based on the achievement of certain 2026 net sales targets. Approximately 100 employees transferred to Laborie as part of this transaction.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In March 2025, we acquired from Biogen the regulatory and commercial rights in the United States for Tofidence, a biosimilar to Actemra2 (tocilizumab), for intravenous infusion. Tofidence, launched in the U.S. market in May 2024, is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. Under the terms of the agreement with Biogen, we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the product developer for Tofidence. In the first quarter of 2025, we recognized an intangible asset of $51 million, related to the upfront payment to Biogen, which will be amortized over 10 years.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
•Singulair, primarily attributable to price reductions in China and Japan, as well as lower demand outside of the United States resulting from increased competition and less favorable medical guidelines; and
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
On October 28, 2024, we acquired Dermavant, a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s novel product, Vtama, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. Food and Drug Administration (the “FDA”) in May 2022. In December 2024, the FDA approved Vtama for the treatment of atopic dermatitis, also known as eczema, in adults and children two years of age and older. Atopic dermatitis is one of the most common inflammatory dermatological conditions in adults, presenting a higher disease burden for women compared to men. The acquisition allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Consideration for Dermavant consists of the upfront payment of $175 million and a $75 million milestone payment upon regulatory approval, as well as payments of up to $950 million for the achievements of certain commercial milestones, tiered royalties on net sales, and the assumption of liabilities, including certain debt obligations, which were accounted for at fair value on the acquisition date.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
During the fourth quarter of 2024, the regulatory milestone related to Vtama’s atopic dermatitis indication, which was recorded as part of contingent consideration at fair value, was achieved and recorded in Accrued and other current liabilities. In January 2025, we paid $75 million related to the milestone.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In the fourth quarter of 2024, we recognized an additional intangible asset of $24 million, related to a sales-based milestone that was deemed probable and was related to an assumed licensing agreement. The intangible asset will be amortized over 11 years.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In September 2024, we entered into license and supply agreements with Centergene, pursuant to which we acquired the exclusive commercialization rights to Centergene’s investigational asset, SJ02, in China. SJ02 is a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP) designed for controlled ovarian stimulation (“COS”) in combination with a GnRH antagonist. It is used to facilitate the development of multiple follicles in women undergoing ART programs. Under the terms of the agreement, we will pay $12 million, of which $6 million was paid in the fourth quarter of 2024. In addition, the remaining $6 million is payable upon obtaining the manufacturing license, which is refundable if thereafter either the regulatory approval is not obtained or marketing authorization cannot be transferred. We may owe additional regulatory and sales-based milestones to Centergene of up to $170 million under the terms of the license and supply agreements. We will recognize regulatory and sales-based milestones when the achievement is probable.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In December 2023, we announced an agreement with Lilly to become the sole distributor and promoter of the migraine medicines Emgality and Rayvow in Europe. Lilly will remain the marketing authorization holder and will manufacture the products for sale. Under the terms of the agreement, we paid an upfront payment of $50 million upon closing of the transaction in January 2024, and will recognize sales-based milestones when the achievement is deemed probable. In the first quarter of 2024, we recognized an intangible asset of $220 million, comprised of the $50 million upfront payment and $170 million of sales-based milestones that were deemed probable. The intangible asset will be amortized over 10 years.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In August of 2024, we expanded our agreement with Lilly to become the sole distributor and promoter for Emgality in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey, and the United Arab Emirates. We paid an upfront payment of $23 million for the expansion of territory upon closing of the transaction in August 2024, and will recognize sales-based milestones when the achievement is deemed probable. In the third quarter of 2024, we recognized an additional intangible asset of $113 million, comprised of the $23 million upfront payment and $90 million related to the sales-based milestones that were deemed probable. The intangible asset will be amortized over 10 years.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
As of December 31, 2024, we had accrued $20 million in Accrued and Other current liabilities and $240 million in Other noncurrent liabilities in total related to the probable sales-based milestones. In January 2025, we paid $20 million related to the milestones.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Nexplanon, due to increased demand, favorable price and discount rates in the United States, increased demand and favorable price in international markets and an increase in demand in our institutional business in Africa;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Diprospan, due to recovery from the manufacturing issues resulting from the regulatory inspection finding at the Heist manufacturing location that impacted the manufacturing of selected injectable steroid brands in the first quarter of 2023 (the “Market Action”).
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
Interest expense decreased 1% 3% for the year ended December 31, 2024, 2025, compared to 2023, reflecting 2024, and reflects lower interest rates as a result of refinancing a portion of our long-term debt in the prior year and the impact repurchase and cancellation of approximately $419 million of the 2031 Notes during the second and fourth quarters of 2025 combined with lower reference rates on our cross-currency swaps, partially variable rate debt, offset by interest related to the debt acquired as part of the Dermavant acquisition and approximately $6 million in previously unamortized debt issuance costs related to fees of approximately $3 million associated with the refinancing repurchase and cancellation of our long-term debt. approximately $419 million of the 2031 Notes.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Sales of Vtama Vtama, a cream for the topical treatment of mild, moderate, and severe plaque psoriasis in adults and atopic dermatitis, also known as eczema, in adults and children two years of age and older, were $12 $128 million for the year ended December 31, 2024, reflecting the 2025, as a result of our acquisition of Dermavant in the fourth quarter of 2024. 2024, launch of the atopic dermatitis indication for adults and children two years of age and older in the United States and launch of the topical treatment of plaque psoriasis in adults in Canada in the third quarter of 2025.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Additionally, this section should be read in connection with Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023, 2024, filed with the SEC and on February 28, 2025 (the “Original 2024 Form 10-K”), as amended by Amendment No. 1 thereto, filed on November 10, 2025 (“Amendment No. 1” and, together with the Original 2024 Form 10-K, the “Prior Form 10-K”), which are available on the SEC’s website at www.sec.gov, which includes a discussion regarding our financial condition and results of operations for the years ended December 31, 2023 and 2022. www.sec.gov.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Net cash used in investing activities was $513 $390 million for the year ended December 31, 2024, 2025, compared to $260 $513 million for the same period in the prior year, primarily due to the Dermavant acquisition, the $73 million upfront decreased milestone payments related to the agreement with Lilly and the additional $71 million payments related to milestones, partially offset by lower capital spending as a result of the completion of the implementation of our ERP system. spending.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Sales of Arcoxia, a medicine for the treatment of arthritis and pain, increased 5% declined 2% for the year ended December 31, 2024, 2025, compared to 2023, 2024, primarily due to decreased demand in Latin America and Asia Pacific, partially offset by increased demand in China and favorable pricing in the Asia Pacific region partially offset by a decrease in demand in various international markets. Russia.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Gross profit decreased 1% 11% for the year ended December 31, 2024, 2025, compared to 2023, 2024, due to increased costs to optimize our manufacturing and supply network, the impact of unfavorable price, foreign exchange translation pricing, volume and higher inflation impacts to material and distribution costs product mix, partially offset by increased sales due to volume. foreign exchange.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
We recorded sales of $142 million during Sales increased 60% for the year ended December 31, 2025, compared to 2024, reflecting an increase due to the sales ramp up since its launch in July 2023 in the United States in July 2023 and a modest increase in international markets. demand in Canada and Puerto Rico.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 35% 21% for the year ended December 31, 2024, 2025, compared to 2023, 2024, due to the loss of a customer contract in 2024 and ongoing generic competition and the negative impact of increased government competition, partially offset by favorable discount rates in the United States. States associated with a new agreement.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Worldwide sales of Marvelon and Mercilon, combined oral hormonal daily contraceptive pills not approved or marketed in the United States, but available in certain countries outside the United States, remained consistent declined 5% for the year ended December 31, 2024, 2025, compared to 2023, 2024, as a result of decreased demand in the Middle East, partially offset by increased demand in various international markets offset by slight declines in China and Japan. increased demand and favorable pricing in Asia Pacific.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
For the year ended December 31, 2023 2025, we recognized $6 million in acquired in-process research and development and milestones of $8 million represent the upfront and development milestones milestones, related to the Claria transaction. exit of our agreement with Centergene, due to the evolving fertility landscape in China.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The accrued balances relative to these provisions included in accounts receivable and accrued and other current liabilities were $111 million and $412 million, respectively, at December 31, 2025, and $100 million and $380 million, respectively, at December 31, 2024, $87 million and $417 million, respectively, at December 31, 2023 and $78 million and $307 million, respectively, at December 31, 2022. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Sales of Atozet, a medicine for lowering LDL cholesterol, declined 9% 31% for the year ended December 31, 2024, 2025, compared to 2023, 2024, primarily due to LOE in France, Spain, Spain and Japan and the timing of tenders in the Latin America region Japan, partially offset by increased demand in certain markets Asia Pacific, Latin America and the product launch in Europe. China.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
We anticipate we will continuing to incur costs associated with this separation, including but not limited to accelerated depreciation, exit premiums and fees, technology transfer costs, stability and qualification batch costs, one-time resourcing costs, regulatory and filing costs, capital investment, and inventory stock bridges.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.